CorMedix Inc (CRMD)

[Rapture2020]

It's happening!

CorMedix price target raised to $3 from $2 at H.C. Wainwright. The analyst raised price target for CorMedix to $3 saying the Neutrolin interim readout delivered a "home run."

H.C. Wainwright analyst sees a possibility now for Neutrolin to be filed before the end of this year and to be approved in 2019, versus his original assumption that the drug would not enter the U.S. market prior to 2020.

Further, the news of the clear efficacy signal in the LOCK-IT-100 study could meaningfully accelerate U.S. sales of the product, the analyst adds. He reiterates a Buy rating on CorMedix.